$0.04
arrow_drop_down2.60%Key Stats | |
---|---|
Open | $0.05 |
Prev. Close | $0.04 |
EPS | -1.73 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $0.00 |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.04 | 0.05 |
52 Week Range | 0.00 | 0.18 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.73 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Cingulate Announces Adjournment of Special Meeting
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance